<li>Craig M McDonald, Eduardo Marbán, Suzanne Hendrix, Nathaniel Hogan, Rachel Ruckdeschel Smith, Michelle Eagle, Richard S Finkel, Cuixia Tian, Joanne Janas, Matthew M Harmelink, Arun S Varadhachary, Michael D Taylor, Kan N Hor, Oscar H Mayer, Erik K Henricson, Pat Furlong, Deborah D Ascheim, Siegfried Rogy, Paula Williams, Linda Marbán, Russell Butterfield, Anne Connolly, Francesco Muntoni, Nanette C. Joyce, Maya Evans, Mehrdad Abedi, Prasanth Surampudi, Sanjay Jhawar, Jonathan G. Dayan, Colleen Anthonisen, Erica Goude, Alina Nicorici, Omaid Sarwary, Poonam Prasad, Jayoon Baek, Andrew Newton, Hannah Johnson, Kyle Kusmik, Lauri Filar, Angie Edmondson, Irina Rybalsky, Wendy Chouteau, Anthony F. Giordano, Aixa Rodriguez, Kristan Anderson, Germaine Wezel, Melisa Vega, Julie Duke, Jorge Collado, Matthew Civitello, Julie Wells, Erika Pyzik, Rebecca Rehborg, Michelle Brown, Jennifer Van Eyk, Russell G. Rogers. <strong>Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial</strong>. <em>The Lancet</em>, 2022; 399 (10329): 1049 DOI: <a href="http://dx.doi.org/10.1016/S0140-6736(22)00012-5" rel="nofollow" target="_blank">10.1016/S0140-6736(22)00012-5</a>
</li>